Letter to the Editor
Drug-eluting balloons for coronary artery disease: an updated meta-analysis of randomized controlled trials

https://doi.org/10.1016/j.ijcard.2013.03.180Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (6)

  • Endovascular drug-delivery and drug-elution systems

    2021, Biomechanics of Coronary Atherosclerotic Plaque: From Model to Patient
  • Assessing the influence of atherosclerosis on drug coated balloon therapy using computational modelling

    2021, European Journal of Pharmaceutics and Biopharmaceutics
    Citation Excerpt :

    Several clinical trials have found DCBs to be superior to balloon angioplasty (BA) in the treatment of de novo and in-stent restenotic lesions in both femoropopliteal and below-the-knee occlusive diseases [6,7]. Additionally, DCBs are comparable (not inferior) to DESs and superior to BA in treating coronary in-stent restenosis [8,9]. Despite these encouraging results, there is little evidence to support the use of DCBs for de novo coronary lesions.

The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

View full text